ClinicalTrials.gg
CompletedNCT02560753Updated Jul 30, 2018Results posted

Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

A Phase 1/2 interventional study of T3D-959 in Alzheimer's Disease, sponsored by T3D Therapeutics, Inc.. Completed at 3 sites in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-07-30.

Sponsored by T3D Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,094th of 1,609
36 · median 73
Started
2015
with 71 others
Phase 1/2
67 of 1,940
17 open now
Registered
726th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 1,094th largest by enrollment of the 1,609 interventional ones that give a count, is one of 72 that started in 2015, is one of 67 in phase 1/2, and was the 726th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The study is a randomized, parallel, 4-dose design in subjects with mild-to-moderate Alzheimer's Disease. Subjects will be randomized to one of 4 doses of T3D-959. Subjects will be evaluated for changes from baseline in cerebral metabolic rate of glucose (FDG-PET imaging), functional connectivity of the hippocampus (BOLD-fMRI), and cognitive function (ADAS-Cog11 and DSST) as well as assessed for safety and tolerability to T3D-959.

An expanded access extension is planed to provide access to study medication to subjects who have completed the main study and requested continued use.

Read the detailed description

T3D-959 is an orally-delivered, once-a-day administered, small molecule dual nuclear receptor agonist that has been shown in animal and Phase 1 studies in normal human subjects to be safe and well tolerated. The purpose of this clinical study in AD patients is to demonstrate mechanistic proof of concept that T3D-959, can produce desired changes in cerebral glucose metabolism and functional connectivity that may indicate potential for cognitive improvement. The therapeutic approach to be tested is based on two suppositions; (A) ameliorating multiple pathologies in the disease with a single therapy may provide a superior clinical benefit than therapeutic approaches which target a single pathology and (B) correcting insulin resistance in the brain, (highly correlated with AD and potential key driver of AD pathophysiology) and peripherally may be disease remedial.

The brain requires integral insulin signaling for metabolic homeostasis and neuronal plasticity. Insulin resistance disrupts energy balance and signaling networks needed for a broad range of functions. Impaired insulin signaling in neurons enhances apoptosis, promotes oxidative cell death induced by Abeta1-42, increases secretion of Abeta1-42, blocks removal of extracellular Abeta oligomers and increases plaque loads. A growing body of evidence suggests that brain insulin resistance promotes or possibly is the trigger of key pathologies in AD and is supported by observed changes in levels of insulin signaling molecules in AD forebrains and associated changes in memory. Pre-clinical studies in animals have demonstrated the insulin sensitizing activity of T3D-959 and ability to improve multiple pathologies of AD in a rat model of disease.

This non-placebo controlled trial will be conducted in one to three clinical centers. Thirty six (36) patients with mild-to-moderate Alzheimer's disease will be randomly assigned to once daily, orally administered treatment with 3mg, 10mg, 30mg or 90mg doses of T3D-959. Participants will be treated for two weeks and will undergo at baseline and at two weeks; FDG-PET scans to measure brain glucose metabolism, BOLD fMRI scans to measure functional connectivity of the hippocampus, venous blood draws for biomarker analysis and ApoE genotyping, and ADAS-Cog11 and DSST cognitive testing. For monitoring potential toxicities of the drug subjects will undergo physical examination, neurological examination, adverse event review, blood chemistries, and pharmacokinetic (PK) analyses for T3D-959 plasma levels.

BOLD fMRI definition of terms:

GoF (Goodness of Fit): The degree to which the spatial extent and magnitude of one subject's default mode network (DMN) regions matches the one of an elderly control group.

Hippo-PreC Link (Hippocampus - Precuneus Link): The resting-state BOLD signal correlation strength between hippocampus and precuneus regions of interest.

GlobEff_DMN: (Global Efficiency from DMN Regions): The global efficiency among 11 pre-defined default mode network regions.

GlobEff_AAL: (Global Efficiency from AAL Regions): The global efficiency among 90 pre-defined cerebral regions based on automated anatomical labeling.

ALFF_lPCC_PreC: Amplitude of Low Frequency Fluctuations (ALFF) from left posterior cingulate cortex (PCC) and precuneus (PreC).

ALFF_rPCC_PreC: ALFF from right PCC and precuneus. fALFF_lPCC_PreC: Ratio ALFF from left PCC and precuneus. fALFF_rPCC_PreC: Ratio ALFF from right PCC and precuneus. ReHo_lPCC_PreC: Regional Homogeneity in left PCC and PreC. ReHo_rPCC_PreC: Regional Homogeneity in right PCC and PreC. ALFF_lIPL: ALFF from left inferior parietal lobule (IPL). ALFF_rIPL: ALFF from right IPL. fALFF_lIPL: Ratio ALFF from left IPL. fALFF_rIPL : Ratio ALFF from right IPL. ReHo_lIPL: Regional Homogeneity in left IPL. ReHo_rIPL: Regional Homogeneity in right IPL.

Expanded Access Extension: This is an open label 10 visit extension for up to 5 subjects who have completed the T3D959-201 protocol and whose caregivers and physician requested their continued treatment in an expanded access protocol. All subjects enrolled in this study will be treated with a 15mg q.d. dose of T3D959 for six months, regardless of their assigned dose level from the main study. A continued risk/benefit assessment by the investigator will be conducted at each visit to determine the need for treatment continuation. Subjects will be assessed for safety and tolerability to T3D-959 and evaluated for changes from baseline cognitive function via ADAS-Cog11 and DSST testing and global change via CIBIC-plus testing.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets criteria for mild-to-moderate AD with (MMSE) score of 14 through 26
  • Clinical Dementia Rating = 0.5 to 2.0
  • Modified Hachinski less than or equal to 4
  • A clinical diagnosis of AD per NINCDS-ADRDA criteria
  • Washout of psychoactive medication (other than anti-depressants): at least 4 weeks prior to baseline
  • Stability of all permitted medications for 4-12 weeks prior to baseline
  • Visual and auditory acuity adequate for neuropsychological testing
  • Home monitoring available for supervision of medications

Exclusion criteria

Exclusion Criteria:

  • Unstable diabetes or insulin use
  • Unable to participate in FDG-PET scanning
  • Inability to undergo a clinical MRI of the brain
  • Diagnosis of significant neurological/psychiatric disease other than AD
  • History of moderate or severe congestive heart failure, class III or IV, within 12 months prior to baseline.
  • Previous cardiovascular event within the past 6 months prior to baseline
  • Subject is pregnant, or lactating.
  • and/or AST levels that are twice the ; levels that exceed 2 mg/dL; serum creatinine >1.5 mg/dL in men or > 1.4 mg/dL in women.
  • Current or history of severe or unstable disorder (medical or psychiatric) requiring treatment that may make the subject unlikely to complete the study.
  • Current use of fluvoxamine.
  • Current unstable use of warfarin.
  • Current use (within 30 days of baseline, visit 2) of certain highly protein-bound medications
  • within the last 5 years (other than non-melanoma skin cancer, stable, non-progressive prostate cancer not requiring treatment or in situ cervical cancer).
  • Known history of , , or .
  • Blood pressure greater than 160/100 mmHg.
  • Known or suspected intolerance or to the study drugs, closely related compounds, or any of their stated ingredients.
  • History of alcohol, drug abuse or dependence (except nicotine dependence) within 2 years.
  • amyloid lowering therapies use within two months prior to baseline
  • Have participated in any other investigational study or received an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to baseline
  • Any surgical or medical condition which may significantly alter the absorption of any drug substance
  • Resides in hospital or moderate to high dependency continuous care facility.
  • Non ambulatory, or wheelchair-bound
  • History of swallowing difficulties.
  • Evidence of pathology that in the investigator's opinion could interfere with the study results or put the subject's safety at risk.

Expanded Access Extension :

Subjects must continue to meet the main study inclusion/exclusion criteria to insure continued safety to continue on a 6 months study extension

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    T3D-959 3mg

    Nine subjects will take 3mg by mouth once daily for two weeks, with or without food.

    Drug: T3D-959

  • Experimental
    T3D-959 10mg

    Nine subjects will take 10mg by mouth once daily for two weeks, with or without food.

    Drug: T3D-959

  • Experimental
    T3D-959 30mg

    Nine subjects will take 30mg by mouth once daily for two weeks, with or without food.

    Drug: T3D-959

  • Experimental
    T3D-959 90mg

    Nine subjects will take 90mg by mouth once daily for two weeks, with or without food.

    Drug: T3D-959

Interventions

  • The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)

06

What researchers measure

Primary outcomes

  1. Change From Baseline (End of Treatment - Baseline) for FDG-PET Imaging With Whole Brain and White Matter as Reference Region

    Changes in relative brain glucose metabolism (delta R CMRgl) were measured by FDG-PET. At each time point, a ratio of the PET reading in a pre-defined region of interest (sROI), known to be affected by AD, and in a reference region (RR) that is spared in AD, is determined. This ratio is defined as "sROI index" (spared region). A second RR, brain white matter (WM), was also used in this calculation: sROI index" (WM) value. delta sROI is defined as change in the sROI index values, over the treatment period. In this study we are looking for changes in delta sROI with increasing doses of T3D-959. Dose dependent changes in delta sROI (AD spared) are compared to those observed with the WM as the RR: delta sROI (WM). Dose related changes in delta sROI suggests T3D-959 is entering the brain and effecting glucose metabolism in a dose dependent fashion.

    Time frame: after 14 days of treatment

  2. The Effect of Treatment With T3D-959 on Changes in Resting State Blood Oxygen Level Dependent (BOLD) Signal in Functional Magnetic Resonance Imaging (fMRI) of the Brain Areas Associated With Cognitive Tasks.

    Changes in BOLD fMRI parameters such as GoF (see Study Description) over the course of two weeks of treatment, were obtained in this study. BOLD fMRI has been used in cross sectional and longitudinal studies of Alzheimer's subjects, for instance in the Alzheimer's Disease Neuroimaging Initiative studies. However, no studies monitoring Default Mode Networks measured parameters such as GoF, in the context of an effective AD therapeutic, as a result it is difficult to interpret the observed small changes listed in BOLD fMRI parameters obtained in this trial. Instead the changes in the listed BOLD fMRI parameters (EOT - BL) are reported without interpretation. These values represent changes in fMRI connectivity patterns over time and are unitless.

    Time frame: after 14 days of treatment

Secondary outcomes

  1. Change From Baseline in the Score of the Digit Symbol Substitution Test

    The digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment. Scores on the DSST range from 0-93.

    Time frame: after 14 days of treatment

  2. Change From Baseline in the Total Score of the 11-item Alzheimer's Disease Assessment Scale - Cognitive Subscale

    The 11-item Alzheimer's Disease Assessment Scale (ADAS-Cog 11) is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. The score can range between 0 and 70. A higher score indicates more cognitive impairment. A positive change in the score indicates cognitive worsening. The minimum severity score is 0 and the maximum severity score is 70.

    Time frame: after 14 days of treatment

Other outcomes

  1. Safety and Tolerability of Treatment With T3D-959 Over a 2-week Period in Subjects With Mild-to-moderate AD. New

    Number of participants with treatment related adverse events (AEs) as assessed by analysis of adverse events, including symptoms, and abnormal findings on physical and neurological examinations, and standard labs.

    Time frame: after 14 days of treatment

07

Results

Posted Jul 30, 2018

Participant flow

Participant flow — Overall Study
MilestoneT3D-959 3mgT3D-959 10mgT3D-959 30mgT3D-959 90mg
Started99108
Completed8998
Not completed1010

Outcome measures

PrimaryChange From Baseline (End of Treatment - Baseline) for FDG-PET Imaging With Whole Brain and White Matter as Reference Region

Changes in relative brain glucose metabolism (delta R CMRgl) were measured by FDG-PET. At each time point, a ratio of the PET reading in a pre-defined region of interest (sROI), known to be affected by AD, and in a reference region (RR) that is spared in AD, is determined. This ratio is defined as "sROI index" (spared region). A second RR, brain white matter (WM), was also used in this calculation: sROI index" (WM) value. delta sROI is defined as change in the sROI index values, over the treatment period. In this study we are looking for changes in delta sROI with increasing doses of T3D-959. Dose dependent changes in delta sROI (AD spared) are compared to those observed with the WM as the RR: delta sROI (WM). Dose related changes in delta sROI suggests T3D-959 is entering the brain and effecting glucose metabolism in a dose dependent fashion.

Time frame:
after 14 days of treatment
Reported as:
Mean · ratio
Change From Baseline (End of Treatment - Baseline) for FDG-PET Imaging With Whole Brain and White Matter as Reference Region
ratioT3D-959 3mgT3D-959 10mgT3D-959 30mgT3D-959 90mg
delta sROI (AD spared)0.0015 ± 0.020570.0034 ± 0.01671-0.0204 ± 0.01952-0.0293 ± 0.01744
delta sROI (white matter)0.0016 ± 0.040080.0053 ± 0.02471-0.0200 ± 0.01979-0.0355 ± 0.02303
PrimaryThe Effect of Treatment With T3D-959 on Changes in Resting State Blood Oxygen Level Dependent (BOLD) Signal in Functional Magnetic Resonance Imaging (fMRI) of the Brain Areas Associated With Cognitive Tasks.

Changes in BOLD fMRI parameters such as GoF (see Study Description) over the course of two weeks of treatment, were obtained in this study. BOLD fMRI has been used in cross sectional and longitudinal studies of Alzheimer's subjects, for instance in the Alzheimer's Disease Neuroimaging Initiative studies. However, no studies monitoring Default Mode Networks measured parameters such as GoF, in the context of an effective AD therapeutic, as a result it is difficult to interpret the observed small changes listed in BOLD fMRI parameters obtained in this trial. Instead the changes in the listed BOLD fMRI parameters (EOT - BL) are reported without interpretation. These values represent changes in fMRI connectivity patterns over time and are unitless.

Time frame:
after 14 days of treatment
Reported as:
Mean · unitless
The Effect of Treatment With T3D-959 on Changes in Resting State Blood Oxygen Level Dependent (BOLD) Signal in Functional Magnetic Resonance Imaging (fMRI) of the Brain Areas Associated With Cognitive Tasks.
unitlessT3D-959 3mgT3D-959 10mgT3D-959 30mgT3D-959 90mg
GoF (Goodness of Fit)0.0129 ± 0.08528-0.0120 ± 0.06460.0118 ± 0.033750.0076 ± 0.08755
Hippo-PreC Link (Hippocampus - Precuneus Link)-0.1213 ± 0.179040.1320 ± 0.229640.1196 ± 0.23035-0.0349 ± 0.18496
GlobEff_DMN(Global Efficiency from DMN Regions)0.0033 ± 0.00734-0.0036 ± 0.00940-0.0004 ± 0.00926-0.0001 ± 0.00397
GlobEff_AAL(Global Efficiency from AAL Regions)-0.0001 ± 0.00664-0.0006 ± 0.00972-0.0031 ± 0.01060-0.0005 ± 0.00517
ALFF_lPCC_PreC (Amplitude of Low Frequency Fluctua-0.0578 ± 0.12314-0.0190 ± 0.11983-0.0505 ± 0.07463-0.0206 ± 0.10508
ALFF_rPCC_PreC (ALFF from right PCC and precuneus)-0.0752 ± 0.09059-0.0127 ± 0.12127-0.0097 ± 0.08362-0.0325 ± 0.11092
fALFF_lPCC_PreC (Ratio ALFF from left PCC & prec0.0121 ± 0.032460.0068 ± 0.03510-0.0132 ± 0.03955-0.0167 ± 0.03284
fALFF_rPCC_PreC (Ratio ALFF from right PCC & pre-0.0080 ± 0.040940.0084 ± 0.04325-0.0007 ± 0.03913-0.0118 ± 0.04236
ReHo_lPCC_PreC (Regional Homogeneity in left PCC a-0.0665 ± 0.185020.0237 ± 0.14028-0.0369 ± 0.097020.0194 ± 0.20061
ReHo_rPCC_PreC (Regional Homogeneity in right PCC-0.0390 ± 0.06406-0.0663 ± 0.22082-0.0895 ± 0.10541-0.0041 ± 0.15836
ALFF_lIPL (ALFF from left inferior parietal lobule-0.0635 ± 0.094450.0104 ± 0.05763-0.0102 ± 0.12016-0.0401 ± 0.05657
ALFF_rIPL(ALFF from right IPL)-0.0493 ± 0.11288-0.0276 ± 0.127200.0346 ± 0.09654-0.1089 ± 0.13935
fALFF_lIPL (Ratio ALFF from left IPL)-0.0296 ± 0.039880.0164 ± 0.02269-0.0107 ± 0.06563-0.0350 ± 0.04570
fALFF_rIPL (Ratio ALFF from right IPL)-0.0342 ± 0.039120.0061 ± 0.032860.0023 ± 0.02771-0.0395 ± 0.05327
ReHo_lIPL (Regional Homogeneity in left IPL)-0.0694 ± 0.154200.0147 ± 0.14620-0.0249 ± 0.19178-0.0062 ± 0.06575
ReHo_rIPL (Regional Homogeneity in right IPL)-0.0694 ± 0.154200.0147 ± 0.14620-0.0249 ± 0.19178-0.0062 ± 0.06575
SecondaryChange From Baseline in the Score of the Digit Symbol Substitution Test

The digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment. Scores on the DSST range from 0-93.

Time frame:
after 14 days of treatment
Reported as:
Mean · score on a scale
Change From Baseline in the Score of the Digit Symbol Substitution Test
score on a scaleT3D-959 3mgT3D-959 10mgT3D-959 30mgT3D-959 90mg
Change from baseline at end of treatment (day 14)4.429 ± 9.16261.000 ± 5.5000.750 ± 3.61541.125 ± 4.5493
Change from baseline at follow-up (day 21)5.375 ± 8.50113.111 ± 5.01114.000 ± 5.67896.625 ± 11.4385
SecondaryChange From Baseline in the Total Score of the 11-item Alzheimer's Disease Assessment Scale - Cognitive Subscale

The 11-item Alzheimer's Disease Assessment Scale (ADAS-Cog 11) is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. The score can range between 0 and 70. A higher score indicates more cognitive impairment. A positive change in the score indicates cognitive worsening. The minimum severity score is 0 and the maximum severity score is 70.

Time frame:
after 14 days of treatment
Reported as:
Mean · score on a scale
Change From Baseline in the Total Score of the 11-item Alzheimer's Disease Assessment Scale - Cognitive Subscale
score on a scaleT3D-959 3mgT3D-959 10mgT3D-959 30mgT3D-959 90mg
Change from baseline at end of treatment (day 14)-2.367 ± 4.0417-0.552 ± 3.1467-2.709 ± 3.98011.970 ± 5.2191
Change from baseline at follow-up (day 21)-3.409 ± 3.5168-0.624 ± 3.8134-4.119 ± 3.81632.795 ± 4.1567
Other pre-specifiedSafety and Tolerability of Treatment With T3D-959 Over a 2-week Period in Subjects With Mild-to-moderate AD. New

Number of participants with treatment related adverse events (AEs) as assessed by analysis of adverse events, including symptoms, and abnormal findings on physical and neurological examinations, and standard labs.

Time frame:
after 14 days of treatment
Reported as:
Number · participants
Safety and Tolerability of Treatment With T3D-959 Over a 2-week Period in Subjects With Mild-to-moderate AD. New
participantsT3D-959 3mgT3D-959 10mgT3D-959 30mgT3D-959 90mg
Subjects with at Least One Serious Adverse Events0000
Subjects with at Least One Drug-related AE0010
Subjects with at Least One mild AE2010
Subjects with at Least One moderate AE1020
Subjects with at Least One serious AE0000

Adverse events

Collected over pre treatment, during the two weeks of treatment and on follow-up one week after treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T3D-959 3mg0/9 (0%)0/9 (0%)1/9 (11.1%)
T3D-959 10mg0/9 (0%)0/9 (0%)0/9 (0%)
T3D-959 30mg0/10 (0%)0/10 (0%)1/10 (10%)
T3D-959 90mg0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent other events
Most frequent other events
EventT3D-959 3mgT3D-959 10mgT3D-959 30mgT3D-959 90mg
TendonitisMusculoskeletal and connective tissue disorders1/90/90/100/8
Muscular WeaknessMusculoskeletal and connective tissue disorders0/90/91/100/8

Baseline characteristics

Age, Customized
Age, Customized(Participants)T3D-959 3mgT3D-959 10mgT3D-959 30mgT3D-959 90mgTotal
<=65 years22318
65-74 years242210
75-84 years331512
>84 years20406
Sex: Female, Male
Sex: Female, Male(Participants)T3D-959 3mgT3D-959 10mgT3D-959 30mgT3D-959 90mgTotal
Female556420
Male444416
ApoE4 genotype
ApoE4 genotype(Participants)T3D-959 3mgT3D-959 10mgT3D-959 30mgT3D-959 90mgTotal
ApoE4 positive424313
ApoE4 negative475521
08

Study locations

3 sites
  • Brain Matters Research
    Delray Beach, Florida 33445, United States
  • Miami Jewish Health Systems
    Miami, Florida 33137, United States
  • New Hope Clinical Research
    Charlotte, North Carolina 28204, United States
09

References and documents

Publications

  • Tong M, Dominguez C, Didsbury J, de la Monte SM. Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. J Alzheimers Dis Parkinsonism. 2016 Jun;6(3):238. doi: 10.4172/2161-0460.1000238. Epub 2016 Jun 3. PubMed 27525190 ↗
  • Tong M, Deochand C, Didsbury J, de la Monte SM. T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2016;51(1):123-38. doi: 10.3233/JAD-151013. PubMed 26836193 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of May 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2018, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2015
First posted
Sep 25, 2015
Start
Jul 2015
Primary completionActual
May 30, 2016
CompletionActual
Jun 30, 2016
Results first posted
Jul 30, 2018
Last update
Jul 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02560753
Lead sponsor
T3D Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 25, 2015
Start date
Jul 2015
Primary completion
May 30, 2016
Completion
Jun 30, 2016
Results posted
Jul 30, 2018
Last update
Jul 30, 2018

Study contacts

John Didsbury, Ph.D.
study chair · T3DTherapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: T3D-959

Start the discussion